Pre-IPO Research Checklist: Ten Critical Items to Verify in Every Prospectus

The HKEX’s proposed listing regime for specialist technology companies, codified in Chapter 18C of the Listing Rules and effective 31 March 2023, has fundamentally altered the calculus for pre-IPO due diligence. Combined with the SFC’s September 2024 circular on sponsor responsibilities under the Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission (the “Code of Conduct”), the margin for error in prospectus verification has narrowed to zero. A 2024 review by the SFC found that 42% of prospectus submissions for Main Board listings contained material deficiencies in revenue recognition disclosures, forcing at least eight issuers to refile their listing documents and incurring an average delay of 14 trading days. For research analysts, family office principals, and IPO project teams, the prospectus is no longer a marketing document—it is a legal instrument subject to strict liability under the Securities and Futures Ordinance (Cap. 571). The following checklist identifies ten critical verification items that separate a robust pre-IPO thesis from a regulatory liability.

Verification of Corporate Structure and VIE Arrangements

The first line of defence in any prospectus review is the corporate structure diagram. Under HKEX Listing Rule 8.04, an issuer must demonstrate that its business operations are conducted through a legal structure that complies with all applicable laws in its jurisdiction of incorporation and principal place of business. For PRC-based issuers using a Variable Interest Entity (VIE) structure, the HKEX’s Guidance Letter HKEX-GL112-22 imposes additional disclosure requirements. The prospectus must explicitly state whether the VIE structure is permitted under PRC foreign investment laws, and if any regulatory approvals have been obtained from the Ministry of Commerce or the National Development and Reform Commission. A 2023 analysis of 34 prospectuses for PRC tech issuers on the Main Board revealed that 11 contained ambiguous language regarding the enforceability of VIE contractual arrangements. The analyst must verify that the issuer’s legal opinion from PRC counsel is dated within three months of the prospectus filing, as required by Practice Note 21 to the Listing Rules. Any gap in this timeline raises a red flag for potential changes in PRC regulatory interpretation.

Cayman Islands and BVI Holding Company Structures

For issuers incorporated in the Cayman Islands or British Virgin Islands, the prospectus must include a detailed description of the issuer’s constitutional documents and their compliance with HKEX Listing Rule 19.05. The verification process should confirm that the issuer’s memorandum and articles of association do not contain any provision that would restrict the transferability of shares or the declaration of dividends in a manner inconsistent with Hong Kong company law. A 2024 SFC enforcement case against a BVI-incorporated issuer found that its articles of association permitted the board to refuse share transfers without providing reasons, a provision that directly contravened HKEX Listing Rule 2.03(2). The prospectus must also disclose any material differences between the issuer’s home jurisdiction corporate governance standards and those required under Appendix C1 of the Main Board Listing Rules. The analyst should cross-reference the issuer’s constitutional documents against the HKEX’s “Guide on the Disclosure of Corporate Governance Practices in Listing Documents” to identify any gaps.

PRC Onshore Operating Entities and WFOE Structures

The verification of onshore operating entities requires a detailed review of the issuer’s Wholly Foreign-Owned Enterprise (WFOE) structure and its contractual arrangements with the VIE. Under HKEX Listing Rule 8.22, the prospectus must disclose the percentage of the issuer’s revenue, profits, and assets that are derived from the VIE structure. The analyst should calculate these percentages independently using the issuer’s audited financial statements for the most recent three financial years. If the VIE contributes more than 30% of the issuer’s total revenue, the prospectus must include a risk factor specifically addressing the enforceability of the VIE agreements under PRC law. The SFC’s September 2024 circular on sponsor due diligence requires that the sponsor obtain a legal opinion from a qualified PRC law firm confirming that the VIE structure does not violate the PRC Foreign Investment Law or the Catalogue of Industries for Guiding Foreign Investment. The analyst should verify that this legal opinion is included as an exhibit to the prospectus and that it addresses the specific industry restrictions applicable to the issuer’s business.

Financial Statement Integrity and Revenue Recognition

The second critical area is the integrity of the issuer’s financial statements, particularly revenue recognition policies. Under HKEX Listing Rule 8.05, an issuer must meet one of three financial tests: the profit test, the market capitalisation/revenue test, or the market capitalisation/revenue/cash flow test. The prospectus must clearly state which test the issuer is relying on and provide the relevant financial data for each of the three preceding financial years. The analyst should verify that the revenue recognition policies disclosed in the prospectus are consistent with Hong Kong Financial Reporting Standards (HKFRS) 15, Revenue from Contracts with Customers. A 2024 review by the Hong Kong Institute of Certified Public Accountants found that 27% of prospectuses for Main Board listings contained revenue recognition policies that were not fully aligned with HKFRS 15, particularly in the areas of variable consideration and contract modification. The analyst should request the issuer’s revenue recognition memo from the reporting accountant and compare it against the disclosure in the prospectus.

Deferred Revenue and Contract Liabilities

Deferred revenue, classified as a contract liability under HKFRS 15, is one of the most frequently misstated line items in prospectus financial statements. The analyst should calculate the deferred revenue turnover ratio—deferred revenue divided by average daily revenue—for each of the three historical years. A ratio that exceeds 90 days for a technology company with standard subscription terms is a red flag for potential revenue acceleration. The prospectus must disclose the nature of the issuer’s performance obligations and the timing of revenue recognition for each material revenue stream. Under HKEX Listing Rule 11.07, the issuer must also disclose any material changes in its revenue recognition policies during the track record period. The analyst should compare the deferred revenue balance disclosed in the prospectus against the audited financial statements filed with the HKEX to ensure consistency. Any discrepancy greater than 5% between the two documents must be explained in the prospectus.

Related Party Transactions and Connected Transactions

Related party transactions are subject to strict disclosure requirements under HKEX Listing Rule 14A. The prospectus must include a table listing all material related party transactions during the track record period, including the transaction amount, the relationship between the parties, and the pricing basis. The analyst should verify that each transaction is classified as either a continuing connected transaction or a one-off connected transaction under Chapter 14A of the Listing Rules. A 2023 SFC study found that 38% of prospectuses for Main Board listings contained incomplete disclosures of connected transactions, with an average understatement of transaction values by 12.4%. The analyst should request the issuer’s connected transaction register and compare it against the prospectus disclosure. Any transaction exceeding 5% of the issuer’s market capitalisation must be approved by independent shareholders under HKEX Listing Rule 14A.36. The prospectus must include the relevant shareholder approval resolution as an exhibit.

Business Model Sustainability and Market Position

The third verification area focuses on the issuer’s business model and its ability to generate sustainable revenue. Under HKEX Listing Rule 8.04, an issuer must demonstrate that it has a “sufficient level of operations and assets” to warrant a listing. The prospectus must include a detailed description of the issuer’s business model, including its value proposition, target market, and competitive advantages. The analyst should verify that the issuer’s market share data is sourced from an independent third-party research report that meets the standards set out in HKEX Guidance Letter HKEX-GL86-16. The guidance letter requires that the research report be commissioned specifically for the listing and that the research firm disclose its methodology and any conflicts of interest. A 2024 review of 22 prospectuses for consumer goods issuers found that 14 relied on market share data from reports that were more than 18 months old, violating the guidance letter’s requirement for current data. The analyst should confirm that the market share data is dated within six months of the prospectus filing.

Customer Concentration Risk

Customer concentration is a material risk factor that must be disclosed under HKEX Listing Rule 11.07. The prospectus must disclose the percentage of revenue derived from the issuer’s five largest customers for each of the three preceding financial years. If any single customer accounts for more than 30% of the issuer’s total revenue, the prospectus must include a specific risk factor addressing the impact of losing that customer. The analyst should calculate the Herfindahl-Hirschman Index (HHI) for the issuer’s customer base to quantify concentration risk. An HHI above 2,500 indicates a highly concentrated customer base that requires additional disclosure. The prospectus must also disclose the contractual terms with the issuer’s top customers, including the duration of the contracts and any termination provisions. A 2023 SFC enforcement action against a technology issuer found that the prospectus failed to disclose that the issuer’s largest customer had a contractual right to terminate its agreement with 30 days’ notice, a fact that materially affected the issuer’s revenue stability.

Supplier and Raw Material Dependency

Supply chain concentration is equally critical. Under HKEX Listing Rule 11.07, the prospectus must disclose the percentage of cost of goods sold attributable to the issuer’s five largest suppliers. If any single supplier accounts for more than 25% of the issuer’s total purchases, the prospectus must include a risk factor addressing the potential disruption to the issuer’s operations. The analyst should verify that the issuer has identified alternative suppliers and that the prospectus discloses the lead time required to switch suppliers. For manufacturing issuers, the prospectus must also disclose the availability and pricing of key raw materials. A 2024 analysis of 18 industrial issuers on the Main Board found that 7 did not disclose the geographic concentration of their suppliers, a material omission given the ongoing trade tensions between the PRC and the United States. The analyst should request the issuer’s supply chain risk assessment and compare it against the prospectus disclosure.

Use of Proceeds and Working Capital Adequacy

The fourth verification area is the issuer’s use of proceeds and working capital adequacy. Under HKEX Listing Rule 11.07, the prospectus must include a detailed breakdown of the intended use of the net proceeds from the listing, with specific percentages allocated to each category. The analyst should verify that the use of proceeds is consistent with the issuer’s business strategy as described in the prospectus. A 2024 SFC review found that 31% of prospectuses contained use of proceeds statements that were too vague to be meaningful, with categories such as “general corporate purposes” accounting for more than 20% of the total proceeds. The HKEX’s Guidance Letter HKEX-GL86-16 requires that the use of proceeds be broken down into specific categories, such as research and development, marketing, capital expenditure, and working capital. The analyst should calculate the issuer’s projected cash burn rate based on the use of proceeds and compare it against the issuer’s historical cash flow statements.

Working Capital Sufficiency Statement

The working capital sufficiency statement is one of the most important sections of the prospectus. Under HKEX Listing Rule 8.21A, the issuer’s sponsor must confirm that the issuer has sufficient working capital for at least 12 months from the date of the prospectus. The analyst should verify that the working capital forecast is based on reasonable assumptions, including projected revenue growth rates, gross margins, and operating expenses. A 2023 study by the Hong Kong Monetary Authority found that 22% of issuers that listed on the Main Board between 2020 and 2023 experienced a working capital shortfall within the first 12 months of listing, with an average shortfall of HKD 45.6 million. The analyst should stress-test the working capital forecast by applying a 20% reduction in projected revenue and a 10% increase in operating expenses. If the issuer’s working capital remains positive under these stress conditions, the forecast is likely reasonable.

Capital Expenditure Commitments

The prospectus must disclose any material capital expenditure commitments that the issuer has entered into or plans to enter into. Under HKEX Listing Rule 11.07, the issuer must disclose the nature, amount, and timing of these commitments. The analyst should verify that the capital expenditure commitments are consistent with the issuer’s use of proceeds and business strategy. A 2024 SFC enforcement action against a property developer found that the prospectus failed to disclose HKD 2.3 billion in capital expenditure commitments that the issuer had entered into six months before the listing. The analyst should request the issuer’s board minutes and capital expenditure approval documents to confirm that all material commitments have been disclosed. Any undisclosed commitment exceeding 5% of the issuer’s total assets is a material omission that could result in regulatory action.

Risk Factors and Legal Proceedings

The fifth verification area is the risk factor section and the disclosure of legal proceedings. Under HKEX Listing Rule 11.07, the prospectus must include a dedicated risk factor section that identifies the specific risks that could materially affect the issuer’s business, financial condition, or results of operations. The analyst should verify that the risk factors are specific to the issuer’s business and not generic boilerplate language. A 2024 review by the SFC found that 45% of prospectuses contained risk factors that were identical across multiple issuers in the same industry, indicating a lack of due diligence by the sponsor. The analyst should compare the risk factor section against the issuer’s industry peers to identify any missing risks. For example, a technology issuer that relies on open-source software should include a risk factor addressing the potential for intellectual property claims related to open-source licensing.

Material Litigation and Regulatory Investigations

The prospectus must disclose all material legal proceedings to which the issuer or its subsidiaries is a party. Under HKEX Listing Rule 8.04, the issuer must demonstrate that it is not subject to any legal proceedings that could materially affect its financial condition. The analyst should request the issuer’s legal proceedings register and compare it against the prospectus disclosure. A 2023 SFC enforcement action found that a pharmaceutical issuer failed to disclose a patent infringement lawsuit that had been filed against its subsidiary in the PRC, with potential damages of HKD 120 million. The analyst should also verify that the issuer has disclosed any regulatory investigations by the SFC, the HKMA, or other regulatory bodies. Under the SFC’s Code of Conduct, the sponsor must conduct a search of the issuer’s regulatory history and confirm that no material investigations are pending. The analyst should request the sponsor’s due diligence report on this point.

Intellectual Property and Regulatory Licences

The final verification item is the issuer’s intellectual property portfolio and regulatory licences. Under HKEX Listing Rule 11.07, the prospectus must disclose all material intellectual property owned or licensed by the issuer, including patents, trademarks, copyrights, and trade secrets. The analyst should verify that the issuer has obtained all necessary regulatory licences to conduct its business in each jurisdiction where it operates. A 2024 review of 15 healthcare issuers on the Main Board found that 6 did not disclose that their PRC operating licences were subject to renewal within 12 months of the listing, a material omission that could affect the issuer’s ability to continue operations. The analyst should request copies of the issuer’s key licences and confirm that they are valid for at least 12 months from the date of the prospectus. Any licence that is due for renewal within this period must be disclosed as a risk factor.

Actionable Takeaways

1. Verify that the VIE structure disclosure includes a PRC legal opinion dated within three months of the prospectus filing, as required by HKEX Guidance Letter HKEX-GL112-22 and the SFC’s September 2024 sponsor circular.
2. Calculate the deferred revenue turnover ratio independently and flag any ratio exceeding 90 days for a subscription-based business as a potential revenue recognition issue under HKFRS 15.
3. Compare the issuer’s connected transaction register against the prospectus disclosure and confirm that all transactions exceeding 5% of market capitalisation have obtained independent shareholder approval under HKEX Listing Rule 14A.36.
4. Stress-test the working capital sufficiency statement by applying a 20% revenue reduction and a 10% expense increase, and require the sponsor to explain any resulting deficit.
5. Request the issuer’s legal proceedings register and regulatory history search report to ensure that all material litigation and investigations have been disclosed in the risk factor section.